You are currently viewing the summary.
View Full TextLog in to view the full text
AAAS login provides access to Science for AAAS members, and access to other journals in the Science family to users who have purchased individual subscriptions.
Register for free to read this article
As a service to the community, this article is available for free. Existing users log in.
More options
Download and print this article for your personal scholarly, research, and educational use.
Buy a single issue of Science for just $15 USD.
This article has a correction. Please see:
Summary
The biotechnology company Celera has generated controversy by reporting that it will sequence the human genome in 3 years with the aid of 230 new high-throughput DNA sequencing machines, well before the efforts of the Human Genome Project are slated to be competed. Now J. C. Mullikin and A. A. McMurray report their evaluation of this sequencer, the ABI 3700 from Perkin-Elmer.
